Rare disease drug recalled in Ireland after Japan deaths
Amgen's drug Tavneos, used for rare autoimmune diseases, has been recalled in Ireland and France after being linked to 20 deaths in Japan. The European Medicines Agency and the FDA have raised concerns about its risks, leading to its withdrawal in several regions. Amgen and its partner Kissei Pharmaceutical have acknowledged the deaths but note some had no confirmed link to the drug.
How this was made
The 30-second read
Why it matters
The recall signals regulatory risk and could lead to a forced US withdrawal, pressuring Amgen's share price.
Market read
Regulatory recall of a key product may trigger sell‑offs in Amgen and affect biotech sentiment.
What to watch
Amgen's diversified portfolio and potential insurance recoveries could mitigate the hit.
Background
Tavneos, Amgen's drug for severe autoimmune diseases, faced a European Medicines Agency warning and subsequent recall in Ireland after 20 deaths were reported in Japan.
Ticker impact
Amgen's rare disease drug Tavneos is being recalled in Ireland and faces potential forced withdrawal in the US after deaths in Japan.
downward pressure
Recall and possible FDA action represent a material regulatory risk for a flagship product.
Market effects
Biotech sector may see heightened scrutiny on rare disease drugs.
European markets could react to the recall; US market impact tied to Amgen.
Regulatory actions on a major biotech could influence global risk sentiment.
Counterpoint
The recall may be limited in scope and not materially affect Amgen's broader pipeline.
Key entities
- CompanyAmgen
US biotech firm manufacturing Tavneos.
- RegulatorHPRA
Health Products Regulatory Authority in Ireland ordering the recall.
